CLYM
Climb Bio Inc.

341
Mkt Cap
$291.86M
Volume
564,974.00
52W High
$8.04
52W Low
$1.05
PE Ratio
-6.90
CLYM Fundamentals
Price
$6.11
Prev Close
$6.98
Open
$6.92
50D MA
$5.78
Beta
1.03
Avg. Volume
634,838.61
EPS (Annual)
-$0.8826
P/B
1.82
Rev/Employee
$0.00
$170.71
Loading...
Loading...
News
all
press releases
Climb Bio (CLYM) Expected to Announce Quarterly Earnings on Tuesday
Climb Bio (NASDAQ:CLYM) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 24. (View Earnings Report at...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Climb Bio Highlights Budoprutug and CLYM116 Milestones, Sets Up Rich Data Year in 2026
Climb Bio (NASDAQ:CLYM) used a presentation at the Leerink Partners Global Healthcare Conference to outline its strategy around two immune-focused programs and to preview a series of data readouts...
MarketBeat·8d ago
News Placeholder
What is HC Wainwright's Forecast for Climb Bio Q1 Earnings?
Climb Bio, Inc. (NASDAQ:CLYM - Free Report) - Investment analysts at HC Wainwright decreased their Q1 2026 earnings per share estimates for shares of Climb Bio in a report issued on Tuesday, March...
MarketBeat·10d ago
News Placeholder
Climb Bio (NASDAQ:CLYM) Shares Gap Up Following Analyst Upgrade
Climb Bio (NASDAQ:CLYM) Shares Gap Up on Analyst Upgrade...
MarketBeat·10d ago
News Placeholder
Q1 Earnings Forecast for Climb Bio Issued By HC Wainwright
Climb Bio, Inc. (NASDAQ:CLYM - Free Report) - HC Wainwright issued their Q1 2027 earnings estimates for Climb Bio in a report issued on Tuesday, March 10th. HC Wainwright analyst R. Selvaraju...
MarketBeat·11d ago
News Placeholder
Climb Bio (NASDAQ:CLYM) Hits New 52-Week High After Analyst Upgrade
Climb Bio (NASDAQ:CLYM) Sets New 52-Week High After Analyst Upgrade...
MarketBeat·11d ago
News Placeholder
Climb Bio (NASDAQ:CLYM) Price Target Raised to $15.00
HC Wainwright upped their target price on Climb Bio from $11.00 to $15.00 and gave the company a "buy" rating in a report on Tuesday...
MarketBeat·12d ago
News Placeholder
Climb Bio (NASDAQ:CLYM) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS
Climb Bio (NASDAQ:CLYM - Get Free Report) issued its earnings results on Thursday. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.06...
MarketBeat·15d ago
News Placeholder
Climb Bio (NASDAQ:CLYM) Price Target Raised to $12.00
Robert W. Baird raised their target price on Climb Bio from $9.00 to $12.00 and gave the stock an "outperform" rating in a research report on Friday...
MarketBeat·15d ago
News Placeholder
Wedbush Begins Coverage on Climb Bio (NASDAQ:CLYM)
Wedbush began coverage on shares of Climb Bio in a report on Thursday. They issued an "outperform" rating and a $12.00 target price for the company...
MarketBeat·16d ago
<
1
2
...
>

Latest CLYM News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.